Imagine a way to check if a heart stent is still working without needing surgery or X-rays. This device acts like a radar, reading the electronic signature of the stent through the skin in seconds. It catches blockages early, long before a patient feels sick or suffers a heart attack.
Stent failures occur in 30% of cases but remain undetected until 90% dysfunction, leading to strokes or death. Current detection requires invasive, expensive, and risky hospital procedures.
A microwave-based medical device (WAEVE System) including a proprietary Vector Network Analyzer and specialized antennas for non-invasive stent monitoring.
If you are a cardiology clinic dealing with the risk of undetected stent failure in 30% of cases — this project developed the WAEVE System that reads stent signatures in less than 5 seconds. This allows you to shift from reactive to proactive care during regular visits.
If you are a hospital dealing with the high cost and 24-hour recovery time of invasive catheter angiography — this project developed a non-ionizing device that monitors stents non-invasively. This reduces the need for anesthesia and X-ray exposure for routine checks.
If you are a MedTech firm dealing with high costs of third-party components — this project developed a proprietary Vector Network Analyzer (VNA) to reduce manufacturing costs. This creates a more cost-effective path to producing monitoring hardware.
Based on available project data, the system reduces costs by replacing invasive catheter angiography, which requires anesthesia and 24-hour hospitalization, with a non-invasive check taking less than 5 seconds.
The company has established a supplier agreement to manufacture WAEVE System units and is developing its own proprietary Vector Network Analyzer to lower production costs.
Based on available project data, the company is developing proprietary hardware (VNA) and software, though specific patent numbers are not listed.
The project is performing a regulatory clinical trial to obtain the CE mark for the European market.
The project period runs from 2024-02-01 to 2026-07-31, with a pilot study of 30 patients finishing in early 2024.
The project is led by a single Spanish SME, NIMBLE Diagnostics SL, with a 100% industry ratio. This lean structure suggests a fast-track commercialization approach, focusing on internal development of hardware and software rather than academic partnerships.
Contact NIMBLE Diagnostics SL in Spain
Contact us to explore licensing or partnership opportunities with NIMBLE Diagnostics.
